403 filings
ARS
2023 FY
KA
Kineta Inc
26 Apr 24
Annual report to shareholders
4:06pm
DEFA14A
KA
Kineta Inc
26 Apr 24
Additional proxy soliciting materials
4:03pm
DEF 14A
KA
Kineta Inc
Definitive proxy
26 Apr 24
4:00pm
8-K
KA
Kineta Inc
24 Apr 24
Entry into a Material Definitive Agreement
4:00pm
8-K
KA
Kineta Inc
18 Apr 24
Departure of Directors or Certain Officers
4:00pm
8-K
d2w0np or2gxg39f012h
8 Apr 24
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
4:02pm
8-K
km9ej5
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
wam8wyyqviu m0
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
8-K
mwl8v rbpts
29 Feb 24
Kineta Announces Restructuring and Exploration of Strategic Alternatives
7:00am
8-K
w0wvhos
17 Jan 24
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
8:30am
8-K
65aqf2
5 Jan 24
Regulation FD Disclosure
4:30pm
8-K
vq5vb
15 Dec 23
Entry into a Material Definitive Agreement
8:30am
EFFECT
v803z 6efd13d469zz
15 Nov 23
Notice of effectiveness
12:15am
424B3
f0wnw9kyq vxvgwj9
13 Nov 23
Prospectus supplement
5:28pm
UPLOAD
24fi jtxki
9 Nov 23
Letter from SEC
12:00am
CORRESP
vmrqi5
9 Nov 23
Correspondence with SEC
12:00am
8-K
319ae4wb
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am